Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants

Yamamoto, 1997, A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity, Proc. Natl. Acad. Sci. USA, 94, 5267, 10.1073/pnas.94.10.5267 Yamamoto, 1997, Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity, J. Exp. Med., 185, 1203, 10.1084/jem.185.7.1203 Chong, 1998, LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp, Vaccine, 16, 732, 10.1016/S0264-410X(97)00255-7 Cardenas-Freytag, 1999, Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis, Infect. Immun., 67, 826, 10.1128/IAI.67.2.826-833.1999 Freytag, 1999, Bacterial toxins as mucosal adjuvants, Curr. Top. Microbiol. Immunol., 236, 215 Cheng, 1999, The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin, Vaccine, 18, 38, 10.1016/S0264-410X(99)00168-1 Stevens, 1996, Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADP-ribosyltransferase activity and interaction with ADP-ribosylation factors, Infect. Immun., 67, 259, 10.1128/IAI.67.1.259-265.1999 Sasaki, 1998, Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine, Infect. Immun., 66, 823, 10.1128/IAI.66.2.823-826.1998 VanCott, 1998, HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160, J. Immunol., 60, 2000, 10.4049/jimmunol.160.4.2000 Michalek, 1983, Oral adjuvants enhance IgA responses to Streptococcus mutans, Mol. Immunol., 20, 1009, 10.1016/0161-5890(83)90042-1 Morisaki, 1983, Effective immunity to dental caries: enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants, Infect. Immun., 40, 577, 10.1128/IAI.40.2.577-591.1983 Ogawa, 1989, Mucosal and systemic immune responses in BALB/c mice to Bacteroides gingivalis fimbriae administered orally, Infect. Immun., 57, 3466, 10.1128/IAI.57.11.3466-3471.1989 Fukushima, 1996, Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus, Vaccine, 14, 485, 10.1016/0264-410X(95)00236-T Isaka, 1998, Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit, Vaccine, 16, 1620, 10.1016/S0264-410X(98)00066-8 Isaka, 1999, Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid, Vaccine, 17, 944, 10.1016/S0264-410X(98)00280-1 Sasaki, 1998, Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes, J. Virol., 72, 4931, 10.1128/JVI.72.6.4931-4939.1998 McNeal, 1998, Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21, Virology, 243, 158, 10.1006/viro.1998.9060 McCluskie, 1998, CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice, J. Immunol., 161, 4463, 10.4049/jimmunol.161.9.4463 McCluskie, 1999, CpG DNA as mucosal adjuvant, Vaccine, 18, 231, 10.1016/S0264-410X(99)00194-2 Horner, 1998, Immunostimulatory DNA Is a Potent Mucosal Adjuvant, Cell Immunol., 190, 77, 10.1006/cimm.1998.1400 Moldoveanu, 1998, CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus, Vaccine, 16, 1216, 10.1016/S0264-410X(98)80122-9 Spangler, 1992, Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin, Microbiol. Rev., 56, 622, 10.1128/MR.56.4.622-647.1992 Snider, 1995, The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins, Crit. Rev. Immunol., 15, 317, 10.1615/CritRevImmunol.v15.i3-4.70 Lycke, 1992, The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity, Eur. J. Immunol., 22, 2277, 10.1002/eji.1830220915 Holmgren, 1993, Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems, Vaccine, 11, 1179, 10.1016/0264-410X(93)90039-Z Verweij, 1998, Musosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen, Vaccine, 16, 2069, 10.1016/S0264-410X(98)00076-0 Tochikubo, 1998, Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin, Vaccine, 16, 150, 10.1016/S0264-410X(97)00194-1 Tamura, 1994, Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine, Vaccine, 12, 419, 10.1016/0264-410X(94)90118-X Tamura, 1994, Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine, Vaccine, 12, 1083, 10.1016/0264-410X(94)90177-5 Krieg, 1995, CpG motifs in bacterial DNA trigger direct B-cell activation, Nature, 374, 546, 10.1038/374546a0 Klinman, 1996, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma, Proc. Natl. Acad. Sci. USA, 93, 2879, 10.1073/pnas.93.7.2879 Yi, 1996, CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL, J. Immunol., 157, 4918, 10.4049/jimmunol.157.11.4918 Halpern, 1996, Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha, Cell. Immunol., 167, 72, 10.1006/cimm.1996.0009 Chace, 1997, Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12, Clin. Immunol. Immunopathol., 84, 185, 10.1006/clin.1997.4380 Cowdery, 1996, Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides, J. Immunol., 156, 4570, 10.4049/jimmunol.156.12.4570 Yamamoto, 1992, Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity, J. Immunol., 148, 4072, 10.4049/jimmunol.148.12.4072 Ballas, 1996, Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA, J. Immunol., 157, 1840, 10.4049/jimmunol.157.5.1840 McCluskie, 2000, Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution, Mol. Med., 6, 867, 10.1007/BF03401824 Davis, 1998, CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant Hepatitis B surface antigen, J. Immunol., 160, 870, 10.4049/jimmunol.160.2.870 Hashigucci, 1996, Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin, Vaccine, 14, 113, 10.1016/0264-410X(95)00174-Y De Haan, 1998, Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin, Eur. J. Immunol., 28, 1243, 10.1002/(SICI)1521-4141(199804)28:04<1243::AID-IMMU1243>3.0.CO;2-E Brazolot Millan, 1998, CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice, Proc. Natl. Acad. Sci. USA, 95, 15553, 10.1073/pnas.95.26.15553 Weeranta, 2000, CpG DNA is a novel non-toxic adjuvant which induces stronger immune responses than many conventional adjuvants, Vaccine, 18, 1755, 10.1016/S0264-410X(99)00526-5 McCluskie, 1998, Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes, Viral. Immunol., 11, 245, 10.1089/vim.1998.11.245 Kay, 1996, TH2-type cytokines in asthma, Ann. NY. Acad. Sci., 796, 1, 10.1111/j.1749-6632.1996.tb32561.x Hogg, 1997, The pathology of asthma, APMIS, 105, 10735, 10.1111/j.1699-0463.1997.tb05079.x Simecka, 2000, Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract, Infect. Immun., 68, 672, 10.1128/IAI.68.2.672-679.2000 Sur, 1999, Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides, J. Immunol., 162, 6284, 10.4049/jimmunol.162.10.6284 Jahn-Schmid, 1999, Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen, J. Allergy. Clin. Immunol., 104, 1015, 10.1016/S0091-6749(99)70083-7 Broide, 1998, Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice, J. Immunol., 161, 7054, 10.4049/jimmunol.161.12.7054 Kline, 1998, Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma, J. Immunol., 160, 2555, 10.4049/jimmunol.160.6.2555 Shirota, 2000, Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs, Am. J. Respir. Cell. Mol. Biol., 22, 176, 10.1165/ajrcmb.22.2.3772 Kline, 1999, CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma, J. Allergy. Clin. Immunol., 104, 1258, 10.1016/S0091-6749(99)70022-9